The company said 571,000 people were screened for colon cancer with its noninvasive Cologuard test in 2017.
Investigators identified mutation, expression, and methylation differences in colorectal polyps from individuals with or without colorectal cancer.
Two bacterial species together help feed the development of colon cancer, according to the New York Times.
Investors in Exact Sciences went on a selling spree after CellMax publicized data suggesting its test could outperform Cologuard for the early detection of colorectal cancer.
A new study suggests that Fusobacterium and other microbes may hitch a ride to metastatic sites with primary colorectal cancers, prompting tumor growth.
The company, which beat analyst estimates on both the top and bottom lines, said Cologuard test volume in Q3 2017 rose 136 percent year over year.
The funding will go toward bringing the BA100 test to clinicians. The test can identify patients most likely to respond to the standard of care chemotherapy treatment.
Using a synthetic genetic screen, investigators identified potential drug targets and tumor suppressors in colorectal cancer xenograft models.
Focusing on drugs that appeared to reverse cancer-related gene expression signatures, researchers identified candidate compounds that thwarted cancer cell lines.
The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.
A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.
Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.
In Science this week: analysis of DNA from ancient North Africans, and more.